Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MagMen-II: Magtrace for Sentinel Lymph Node Localization in Melanoma
NCT07552597Phase 3Not yet recruiting
- Sponsor
- Region Västra Götaland
- Start
- Oct 2026
- Primary completion
- Dec 2030
01
Overview
Phase 3, randomised, open-label trial in melanoma (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Sentinel Lymph Node detection at 6 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
melanoma
Beyond the preview
Go deeper on NCT07552597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07552597.